Microdialysis for pharmacokinetic-pharmacodynamic studies

被引:2
|
作者
Yu, W. [1 ]
Cheng, Q. [1 ]
Feng, J. [1 ]
Li, F. [1 ]
机构
[1] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Dept Pharmaceut, Hangzhou 310053, Peoples R China
来源
PHARMAZIE | 2007年 / 62卷 / 12期
关键词
D O I
10.1691/ph.2007.12.7049
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Microdialysis (MD) has become one of the major tools to sample endogenous and exogenous substances in extracellular spaces. It is more suitable for pharmacokinetic-pharmacodynamic (PK-PD) studies than other techniques. This review aims to give an overview of MID for PK-PD (MD/PK-PD) studies, including PK-PD studies, three aspects (principles, recovery, advantages) of MD/PK-PD, and application examples of MD/PK-PD organized by types of drugs and information collected. It can be concluded that MID offers an unique opportunity, to study simultaneously pharmacokinetic (PK) behavior of a drug and its effect on the extracellular levels of endogenous compounds, which may facilitate proof-of-concept demonstrations for target modulation, enhance the rational selection of an optimal drug dose and schedule. In addition, MD/PK-PD can also minimize uncertainties associated with predicting drug safety and efficacy, reduce the high levels of drug attrition during development, accelerate drug approval, and decrease the overall costs of drug development.
引用
收藏
页码:883 / 891
页数:9
相关论文
共 50 条
  • [41] PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF THE ANTICONVULSANT EFFECT
    HOOGERKAMP, AVPW
    ARENDS, RHGP
    VOSKUYL, RA
    DANHOF, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (02) : 602 - 602
  • [42] A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
    Brekkan, Ari
    Lopez-Lazaro, Luis
    Yngman, Gunnar
    Plan, Elodie L.
    Acharya, Chayan
    Hooker, Andrew C.
    Kankanwadi, Suresh
    Karlsson, Mats O.
    AAPS JOURNAL, 2018, 20 (05):
  • [43] Pharmacokinetic-pharmacodynamic modelling of behavioural responses
    Della Paschoa, OE
    Kruk, MR
    Danhof, M
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1998, 23 (02): : 229 - 236
  • [44] Pharmacokinetic-pharmacodynamic values for amoxicillin in pigs
    Papich, Mark G.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2014, 75 (04) : 316 - 316
  • [45] Biomarkers, Validation and Pharmacokinetic-Pharmacodynamic Modelling
    Wayne A. Colburn
    Jean W. Lee
    Clinical Pharmacokinetics, 2003, 42 : 997 - 1022
  • [46] Methodological Issues in Pharmacokinetic-Pharmacodynamic Modelling
    Eric Bellissant
    Véronique Sébille
    Gilles Paintaud
    Clinical Pharmacokinetics, 1998, 35 : 151 - 166
  • [47] A population pharmacokinetic and pharmacokinetic-pharmacodynamic analysis of vupanorsen from phase I and phase II studies
    Ahn, Jae Eun
    Terra, Steven G.
    Liu, Jing
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (07): : 988 - 1000
  • [48] Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling to the Rescue
    Tucker, Geoffrey T.
    ANESTHESIOLOGY, 2014, 120 (04) : 795 - 796
  • [49] Role of the pharmacokinetic-pharmacodynamic relationship in drug development
    Bellissant, E
    Courcier-Duplantier, S
    Blin, O
    THERAPIE, 2002, 57 (04): : 347 - 357
  • [50] A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis
    J. W. S. Cattrall
    E. Asín-Prieto
    J. Freeman
    I. F. Trocóniz
    A. Kirby
    European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 2311 - 2321